Lauren Martz of Nature’s Science Business Exchange (SciBX) interviews Biovista’s Dr Deftereos on “Myelination from neural stem cells”. Read article here.
News
The Path of Least Resistance: Repositioned Drugs Surpass New Brands
Article by PharmExec’s Clark Herman on the 505(b)(2) pathway for drug approval … Aris Persidis, president and co-founder of Biovista, a company focused on the 505(b)(2), adds, “In addition, the first to file patent regulations that will take effect in the US next year are making companies realize that they may be susceptible to competitors … Read More
Biovista announces lunch and panel discussion on Drug Repositioning in Rare and Orphan diseases
Biovista, one of the world leaders in drug repositioning, is hosting a lunch and panel discussion on “Drug Repositioning in Rare and Orphan Diseases”, October 18th in Washington DC. Interested parties are invited to register. The discussion will involve thought leaders from associations such as CFIDS, Partnership for Cures and FARA and will explore if … Read More
Train: CFIDS INNOVATOR SPOTLIGHT
Q&A with K. Kimberly McCleary President & CEO The CFIDS Association of America A 2011 article in The Scientist alerted Suzanne to companies applying informatics to drug repurposing. One of them, Biovista, applied to our 2011 funding opportunity and its proposal to identify non-obvious drug therapies for CFS scored well for scientific and strategic merit. … Read More
Research 1st: Repurposing Old Drugs for CFS
Biovista and its VP for Drug Discovery, Dr. Spyros Deftereos, MD, are featured in an online article in relation to CFIDS Association’s Research Institute Without Walls (RIWW) … The process of drug repurposing, also called “drug repositioning,” can slash the time and cost to bring new therapies to the patients who need them most, says … Read More